格隆汇12月3日丨旺山旺水-B(02630.HK)发布公告，宣布，公司与先声药业(02096.HK)就VV116新适应 症订立许可协议。根据该协议，公司将授予先声药业VV116在大中华区抗呼吸道合胞病毒("RSV")感染 以及抗人偏肺病毒("HMPV")感染适应症的独家许可权益。旺山旺水与先声药业强强联合，发挥各自研 发、生产及商业化的优势，加速VV116的临床开发和商业化进程，以期惠及更多患者。 ...

除非本公告另有界定，否則本公告所用詞彙與招股章程所界定者具有相同涵義。 本公告乃由本公司根據香港法例第571章《證券及期貨條例》項下的《證券及期貨（穩定價格）規 則》第9(2)條作出。 Vigonvita Life Sciences Co., Ltd. 蘇州旺山旺水生物醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2630） 穩定價格期間結束、並無穩定價格行動及超額配股權失效 香港交易及結算所有限公司、香港聯合交易所有限公司（「聯交所」）及香港中央結算有限公司對 本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告 全部或任何部分內容而產生或因倚賴該等內容引致的任何損失承擔任何責任。 本公告不會直接或間接在或向美國（包括其領土及屬地、美國任何州以及哥倫比亞特區）發佈、 刊發或派發。本公告並非亦無意構成或組成於美國或任何其他司法管轄區購買或認購證券的任 何要約或招攬的一部分。發售股份不曾亦不會根據1933年美國證券法（經不時修訂）（「美國證券 法」）或美國任何州或其他司法管轄區的證券法登記，且不得在美國境內提呈發售、出售、抵押 或轉讓，惟獲豁免遵守或毋須 ...

Core Viewpoint - The company has entered into a licensing agreement with Ascletis Pharma Inc. for the exclusive rights to develop and commercialize VV116 for RSV and HMPV infections in Greater China, aiming to accelerate clinical development and commercialization to benefit more patients [1][2]. Group 1: Licensing Agreement - The company grants Ascletis exclusive licensing rights for VV116 in the treatment of RSV and HMPV infections in Greater China [1]. - This collaboration leverages the strengths of both companies in research, production, and commercialization [1]. Group 2: Product Overview - VV116 is an oral nucleoside prodrug that received conditional approval from the National Medical Products Administration (NMPA) in January 2023 for treating mild to moderate COVID-19 infections, with plans for full approval by January 2025 [1]. - VV116 exhibits broad-spectrum antiviral activity, showing effective inhibition against various RNA viruses, including RSV [1]. Group 3: Clinical Trials and Safety - A Phase II clinical trial for VV116 as a treatment for RSV in infants has been completed, leading to its designation as a breakthrough therapy by the NMPA [2]. - Preclinical studies indicate significant antiviral effects of VV116 in vitro and in animal models, along with improvements in lung pathology [2]. - Clinical pharmacokinetic studies demonstrate good oral absorption and linear pharmacokinetics, with no significant impact from infant formula on its main metabolites [2]. - Overall safety in clinical studies is reported to be good, with no severe adverse events noted [2].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 Vigonvita Life Sciences Co., Ltd. 蘇州旺山旺水生物醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2630） 自願公告 與先聲藥業就氫溴酸氘瑞米德韋(VV116)新適應症訂立許可協議 本公告由蘇州旺山旺水生物醫藥股份有限公司（「本公司」或「旺山旺水」）自願作 出，以告知本公司股東及潛在投資者本集團最新業務發展狀況。 本公司董事（「董事」）會（「董事會」）欣然宣佈，本公司與先聲藥業集團有限公司 （「先聲藥業」）就VV116新適應症訂立許可協議（「該協議」）。根據該協議，本公司 將授予先聲藥業VV116在大中華區抗呼吸道合胞病毒（「RSV」）感染以及抗人偏肺 病毒（「HMPV」）感染適應症的獨家許可權益。旺山旺水與先聲藥業強強聯合，發 揮各自研發、生產及商業化的優勢，加速VV116的臨床開發和商業化進程，以期 惠及更多患者。 關於VV116 VV1 ...

Group 1 - The Hong Kong biotechnology sector experienced a widespread decline, with notable drops in several companies' stock prices [1] - Specifically, Gilead Sciences-B fell over 13%, while Sanofi-B dropped more than 10% [1] - Other companies such as Crystal Technology Holdings and Hualing Pharmaceutical-B also saw declines exceeding 6% [1] Group 2 - Gilead Sciences-B's latest price is 11.750, with a market capitalization of 116.56 billion and a year-to-date increase of 290.37% [2] - Sanofi-B's latest price is 7.000, with a market capitalization of 7.44 billion and a year-to-date increase of 102.31% [2] - Crystal Technology Holdings has a latest price of 9.330, a market capitalization of 401.48 billion, and a year-to-date increase of 56.02% [2] - Hualing Pharmaceutical-B's latest price is 3.230, with a market capitalization of 34.13 billion and a year-to-date increase of 121.23% [2] - Other companies like Wangshan Wangshui-B and Sanleaf Biotech-B also reported significant declines, with year-to-date increases of 123.25% and 920.75% respectively [2]

Core Insights - The Hong Kong IPO market showed a marginal recovery in November 2025, with a notable concentration of listings towards the end of the month [2][18] - A total of 53 companies submitted listing applications, with 25 of them in the last week of November [2][18] - 12 new companies successfully listed on the Hong Kong Stock Exchange during this period [2][18] Listing Performance - The top three performers on their first trading day were 旺山旺水 (Wangshan Wangshui) with a gain of 145.73%, 明略科技 (Minglue Technology) at 106.10%, and 量化派 (Quantitative Party) at 88.78% [2][19][21] - Conversely, the companies with the largest declines were 海伟股份 (Haiwei Co.) at -22.97%, 文远知行 (Wenyan Zhixing) at -9.96%, and 小马智行 (Xiaoma Zhixing) at -9.28% [2][19][21] Fundraising Highlights - The top three companies in terms of fundraising were 赛力斯 (Sailis) with approximately 14.283 billion HKD, 小马智行 (Xiaoma Zhixing) at 6.707 billion HKD, and 创新实业 (Innovation Industry) at 5.495 billion HKD [2][19][26]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 蘇州旺山旺水生物醫藥股份有限公司（「本公司」） 呈交日期: 2025年12月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02630 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 66,677,133 | RMB | | 1 RMB | | 66,677,133 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 66,677,133 | RMB | | 1 RMB | | 66,677,133 | | 2. 股份分類 | 普通股 | 股份類別 ...

Core Viewpoint - The company has announced the implementation of H-share full circulation, converting approximately 100.2 million unlisted shares held by 10 shareholders into H-shares, which represents about 59.7983% of the total issued shares as of the announcement date [1] Group 1 - The board of directors approved the proposal for H-share full circulation on November 26, 2025 [1] - The conversion involves shares held by 10 shareholders, totaling approximately 100.2 million shares [1] - The H-share full circulation will significantly increase the liquidity of the company's shares in the market [1]

Core Viewpoint - The company has announced the implementation of H-share full circulation, converting 100 million unlisted shares held by 10 shareholders into H-shares, which represents approximately 59.7983% of the total issued shares as of the announcement date [1] Group 1 - The board of directors approved the proposal for H-share full circulation on November 26, 2025 [1] - The conversion of unlisted shares into H-shares is subject to obtaining all necessary approvals, including filing with the China Securities Regulatory Commission [1] - The company will apply for the listing and trading of these H-shares on the main board of the Stock Exchange of Hong Kong [1] Group 2 - The conversion and listing do not require shareholder approval according to the company's articles of association [1]

Core Viewpoint - The company Wangshan Wangshui-B (02630) announced the implementation of a proposal for full circulation of H-shares, converting 100 million unlisted shares held by 10 shareholders into H-shares, which represents approximately 59.7983% of the total issued shares as of the announcement date [1] Group 1 - The board of directors approved the proposal for full circulation of H-shares on November 26, 2025 [1] - The conversion of the 100 million unlisted shares into H-shares is subject to obtaining all relevant approvals, including filing with the China Securities Regulatory Commission [1] - The company will apply to the Stock Exchange for approval for the listing and trading of the converted H-shares on the main board [1] Group 2 - According to the company's articles of association, the conversion and listing do not require approval from the shareholders' meeting [1]